Dart Group flying high after raising full-year guidance
After what it termed a satisfactory first half of the financial year, the board now expects current market expectations for group profit before foreign exchange revaluation and taxation for the year ending 31 March 2020 to be significantly exceeded.
The first half saw underlying profit rise 3% to £349.8mln from £340.2mln the year before.
2.00pm: Diurnal Group expects to clinch licensing deal in the first half of next year
The company said at its annual general meeting that recent pricing work had reinforced the significant commercial potential for Alkindi and the company's other lead candidate, Chronocort, in the US.
Diurnal's discussions with US partners around its late-stage cortisol deficiency pipeline continue to advance and it expects to conclude a licensing deal during the first half of next year.
12.50pm: Netcall scores after upbeat AGM statement
The shares were up 6.8% at 23.7p following a trading statement issued to coincide with the firm's annual general meeting.
"The group's pipeline is healthy and continues to show growth, driven predominately by cloud-based opportunities. The board is mindful of the current political and economic backdrop and notes that this may have an effect on customer decision making and it continues to monitor the timing of its larger enterprise and product sale contracts,” company chairman, Michael Jackson, told shareholders.
11.55am: NetScientific boosted by news of funding for Glycotest
NetScientific PLC (LON:NSCI) said investee company Glycotest Inc has received a second US$3mln tranche of its US$10mln Series A fundraising round with Chinas Fosun Pharmaceutical.
The cash injection will allow Glycotest to advance towards commercial launch its algorithm-driven test for hepatocellular carcinoma, a form of liver cancer.
Shares in Netscientific were up 9.1% at 6.00p.
10.50am: Iconic Labs in surprising surge after launch of corporate website
The new media and technology business said its website includes details of the company's strategy, its board, and key investor information.